{"ticker": {"uuid": "b909b0d6-ac7c-43e4-b8f0-3908e0989269", "symbol": "NAMS", "name": "NewAmsterdam Pharma Company N.V. Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "NewAmsterdam Pharma publishes obicetrapib Alzheimer\u2019s prevention research presentation", "summary": "NewAmsterdam Pharma has released a research presentation on the use of its CETP inhibitor, obicetrapib, for Alzheimer's prevention. A Phase 3 substudy showed that obicetrapib reduced plasma p-tau217 after 12 months, particularly in APOE4/E4 carriers, and positively impacted other", "url": "https://www.bitget.com/amp/news/detail/12560605512494", "source_name": "Bitget", "published_at": "2026-07-17T09:10:48", "published_display": "17 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. \u2013 MUN:KH6", "summary": "This article provides an analysis of the enterprise value to revenue forward for NewAmsterdam Pharma Company N.V. (MUN:KH6). It highlights financial data and market specifics for the company, listed on the Munich Stock Exchange. The information is presented within a financial dat", "url": "https://www.tradingview.com/symbols/MUN-KH6/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T05:11:58", "published_display": "14 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (NAMSW) for Rule-Based Strategy", "summary": "This article provides a price-driven insight for Newamsterdam Pharma Company N.v. Warrant (NASDAQ: NAMSW), detailing AI-generated trading strategies for different risk profiles. It highlights institutional trading strategies, multi-timeframe signal analysis, and real-time trading", "url": "https://news.stocktradersdaily.com/news_release/98/Price-Driven_Insight_from_NAMSW_for_Rule-Based_Strategy_071426032802_1784014082.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-14T03:11:58", "published_display": "14 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of NewAmsterdam Pharma Company N.V. \u2013 NASDAQ:NAMS", "summary": "This article provides financial information for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), specifically focusing on its forward price-to-sales ratio. It presents various financial data points and market information for the company, accessible through TradingView. The conten", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T08:39:47", "published_display": "12 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company (NAMS) Study Update Summary", "summary": "NewAmsterdam Pharma Company (NAMS) provided an update on its BROOKLYN Phase III trial for obicetrapib, an investigational drug for Heterozygous familial hypercholesterolemia (HeFH). The study demonstrated that obicetrapib significantly reduced LDL-C by 36.3% at 84 days and 41.5% ", "url": "https://quartr.com/events/newamsterdam-pharma-company-n-v-nams-study-update_FL4O0nmu", "source_name": "Quartr", "published_at": "2026-07-10T21:10:48", "published_display": "10 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cambrex-snapdragon-chemistry-q1-scientific-120000213.html", "source_name": "CNW Group", "published_at": "2026-07-07T12:00:00+00:00", "published_display": "07 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma (NAMS) Alzheimer\u2019s Data Push Puts Fair Value Back In Focus", "summary": "NewAmsterdam Pharma (NAMS) is gaining attention due to its upcoming presentation of new obicetrapib data at the Alzheimer\u2019s Association International Conference, highlighting its potential in early Alzheimer's disease prevention. Despite trading at a premium on a price-to-book ba", "url": "https://www.sahmcapital.com/news/content/newamsterdam-pharma-nams-alzheimers-data-push-puts-fair-value-back-in-focus-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-06T06:39:14", "published_display": "06 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAMS - NewAmsterdam Pharma Company NV Latest SEC Filings", "summary": "This article provides the latest SEC filings information for NewAmsterdam Pharma Company NV (NAMS), including its last closing price, various financial metrics, stock performance data, and institutional/insider ownership details. It presents a comprehensive overview of the compan", "url": "https://finviz.com/stock?t=NAMS&ty=lf&p=d&b=1&page=3", "source_name": "Finviz", "published_at": "2026-07-03T17:09:09", "published_display": "03 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "NewAmsterdam Pharma N.V. announced inducement grants of share options and restricted stock units to four new non-executive hires under Nasdaq Listing Rule 5635(c)(4). The grants, made on July 1, 2026, include 28,700 ordinary shares for options with an exercise price of $35.17 and", "url": "https://finance.yahoo.com/healthcare/articles/newamsterdam-pharma-reports-inducement-grants-200100789.html", "source_name": "Market source", "published_at": "2026-07-03T04:40:12", "published_display": "03 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAMS - NewAmsterdam Pharma Company NV Options", "summary": "This article provides detailed financial data and performance metrics for NewAmsterdam Pharma Company NV (NAMS). It includes information on its last closing price, stock performance over various periods, key financial ratios, insider and institutional ownership, and analyst recom", "url": "https://finviz.com/stock?t=NAMS&ta=1&p=d&ty=oc&b=1", "source_name": "Finviz", "published_at": "2026-07-02T21:39:24", "published_display": "02 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma awards stock incentives to four new hires", "summary": "NewAmsterdam Pharma has granted equity awards to four new non-executive hires under its 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards consist of share options for 28,700 ordinary shares with an exercise price of $35.17 and 8,100 restricted st", "url": "https://www.stocktitan.net/news/NAMS/new-amsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-yxmzh17nef3k.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:33", "published_display": "02 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026", "summary": "NewAmsterdam Pharma N.V. announced it will present data on its drug obicetrapib as a potential therapy for early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. The presentations will highlight insights from the BROADWAY trial regarding pr", "url": "https://ca.finance.yahoo.com/news/newamsterdam-pharma-announces-upcoming-presentations-120000585.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-02T05:09:42", "published_display": "02 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is NewAmsterdam Pharma (NAMS) Quietly Reframing Its Alzheimer\u2019s Strategy With Obicetrapib\u2019s Multi\u2011Pathway Data?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T22:56:12+00:00", "published_display": "01 Jul 2026 22:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Announces Upcoming Presentations at the", "summary": "NewAmsterdam Pharma N.V. will present data on its investigational drug obicetrapib for the prevention of early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. The presentations will highlight insights from the BROADWAY trial regarding P-ta", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320530/0/en/newamsterdam-pharma-announces-upcoming-presentations-at-the-alzheimer-s-association-international-conference-aaic-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T11:39:58", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma puts obicetrapib in Alzheimer\u2019s spotlight at AAIC 2026", "summary": "NewAmsterdam Pharma will present multiple obicetrapib data sets related to Alzheimer's prevention at the Alzheimer's Association International Conference (AAIC) 2026 in London. The presentations will cover predictors of P-tau217, undiagnosed Alzheimer\u2019s pathology in cardiovascula", "url": "https://www.stocktitan.net/news/NAMS/new-amsterdam-pharma-announces-upcoming-presentations-at-the-ehajohcf4vdg.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:39:58", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V.", "summary": "This page provides access to NewAmsterdam Pharma Company N.V.'s SEC filings and other corporate documents, including earnings reports and event transcripts from various healthcare conferences. It details the company's financial performance, clinical trial advancements for Obicetr", "url": "https://www.tradingview.com/symbols/BOATS-NAMSW/documents/", "source_name": "TradingView", "published_at": "2026-07-01T10:39:58", "published_display": "01 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/newamsterdam-pharma-apos-obicetrapib-could-155741653.html", "source_name": "MT Newswires", "published_at": "2026-06-30T15:57:41+00:00", "published_display": "30 Jun 2026 15:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Raises Price Target on NewAmsterdam Pharma to $51 From $47, Keeps Outperform, Speculative Risk", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-raises-price-target-newamsterdam-112909411.html", "source_name": "MT Newswires", "published_at": "2026-06-30T11:29:09+00:00", "published_display": "30 Jun 2026 11:29", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NewAmsterdam Pharma Company N.V. \u2013 BOATS:NAMSW", "summary": "This article provides financial information for NewAmsterdam Pharma Company N.V. (NAMSW), specifically highlighting its price to sales forward metric. It also notes that the market for NAMSW is currently closed with no trades. The content is hosted on TradingView, which offers va", "url": "https://www.tradingview.com/symbols/BOATS-NAMSW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:39:50", "published_display": "29 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of NewAmsterdam Pharma Company N.V. \u2013 NASDAQ:NAMS", "summary": "This article provides the \"Price to book forward\" for NewAmsterdam Pharma Company N.V., traded under the NASDAQ symbol NAMS. It appears to be a financial data point from a market overview section, typical for platforms like TradingView. The content is concise, focusing solely on ", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:10:14", "published_display": "28 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. \u2013 NASDAQ:NAMSW", "summary": "This article provides the enterprise value to revenue forward for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW). The data presented shows the value, change, and percentage change for this financial metric. The information is sourced from TradingView, with market data from ICE ", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMSW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:11:04", "published_display": "28 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. \u2013 BOATS:NAMSW", "summary": "The article focuses on the enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. (NAMSW) as listed on the Blue Ocean Alternative Trade System. It provides a financial overview and market information for the company, indicating that the market is currently closed", "url": "https://www.tradingview.com/symbols/BOATS-NAMSW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T07:11:56", "published_display": "28 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of NewAmsterdam Pharma Company N.V. \u2013 LSX:A3DUAC", "summary": "This article provides the \"Price to book forward\" for NewAmsterdam Pharma Company N.V. (LSX:A3DUAC) on the Lang & Schwarz Exchange. The content highlights financial data and indicates that the market was closed with no trades. It also includes general disclaimers about data provi", "url": "https://www.tradingview.com/symbols/LSX-A3DUAC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:09:42", "published_display": "28 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of NewAmsterdam Pharma Company N.V. \u2013 NASDAQ:NAMSW", "summary": "This article provides the enterprise value to EBITDA forward for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW). It presents this financial metric for the company, indicating its market valuation relative to its earnings before interest, taxes, depreciation, and amortization. T", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMSW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:10:04", "published_display": "28 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. Actuals & Estimates (MUN:KH6)", "summary": "NewAmsterdam Pharma Company N.V. (KH6) financial actuals and estimates are detailed, including income statement, balance sheet, and cash flow data, as well as analyst forecasts. The article provides key financial metrics such as earnings per share, revenue, and EBITDA, and states", "url": "https://www.tradingview.com/symbols/MUN-KH6/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T14:41:27", "published_display": "27 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAMS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "NewAmsterdam Pharma Company N.V. (NAMS) stock is currently trading at $33.24, with analysts predicting a future price range between $38.00 and $60.00. The company's stock has seen an 82.04% increase over the last year, and it is expected to release its next earnings report on Aug", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T14:11:04", "published_display": "27 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. Actuals & Estimates (NASDAQ:NAMS)", "summary": "This article provides an overview of NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) including its current stock price, historical performance, financial estimates, and analyst forecasts. It details financial actuals for revenue and earnings, future earnings dates, and general co", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T07:39:32", "published_display": "27 Jun 2026 07:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. Actuals & Estimates (HAM:KH6)", "summary": "This article provides an overview of NewAmsterdam Pharma Company N.V. (HAM:KH6) including its financial actuals and estimates, as well as analyst forecasts. It covers key financial data such as earnings, revenue, net income, and EBITDA, along with historical stock prices and futu", "url": "https://www.tradingview.com/symbols/HAM-KH6/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:32", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. \u2013 LSX:A3DUAC", "summary": "This article provides financial data for NewAmsterdam Pharma Company N.V. (LSX: A3DUAC), specifically focusing on its enterprise value to revenue forward. The content is primarily a data placeholder from TradingView, offering a snapshot of the company's financial overview without", "url": "https://www.tradingview.com/symbols/LSX-A3DUAC/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:10:00", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. Actuals & Estimates (LSX:A3DUAC)", "summary": "This article provides actuals and estimates for NewAmsterdam Pharma Company N.V. (LSX:A3DUAC), detailing financial data, analyst forecasts, and various stock performance metrics. It covers information on the company's stock price, market capitalization, earnings, revenue, and fut", "url": "https://www.tradingview.com/symbols/LSX-A3DUAC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:00", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of NewAmsterdam Pharma Company N.V. \u2013 NASDAQ:NAMS", "summary": "This article provides the \"Price to earnings forward\" value for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS). It specifies that the market is currently closed and no trades have occurred. The content appears to be a stub or a section of a larger financial data display from Tra", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T03:40:39", "published_display": "25 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma (NAMS) CAO exercises options and sells 40,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOZk10UWRIaGp2QW1hclh5MTUtTWZrcUE3Wld4U0ZUMnFxRlNmS3c3QmZfQUtjRWhRZjMwa05mYm5HWHJ1M2t5ajZkTG81M0JoczA2ZDRjdjVNbGtMeHpCcjRSb1ZVQ285TU51enozT01nV1VEVzdVdTlmaU41cEZzWWtEYV9waHpoWGFucE5wUWF4VXhZX1BUQVhlRGhRQ3VyV25mX3h1cF9WcFYzZXdXcXI2UF94c1VzckhjcjBB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNdjlSR3Z1RnQtNUNnSWxfX2RtMGpudUo5NFFXSzVGNXIzVEdVYUs5dkZxME1uQlUtY3Rhb29fd2ZSVEd2R1JnMklPSGd5UkxqR19FUHpyby11RkZ3VUNuQ25xX2hNc1BUZFFVWFRCa25ZQ1AxNTRKT24wLWtTOHQzZDJLamRsTUpReWVtb3l6czdnalZacmR1TFFKUUpPV2NRenY5NHdoZw?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/billionaire-stanley-druckenmiller-likes-small-142953263.html", "source_name": "Insider Monkey", "published_at": "2026-06-08T14:29:53+00:00", "published_display": "08 Jun 2026 14:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/newamsterdam-pharma-announces-upcoming-presentations-120000543.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:00:00+00:00", "published_display": "03 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech NewAmsterdam to appear at two June healthcare investor events", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNVG94TXV4UV9MSVF0UGZ1UjVRUjAxak1TclZaMU5maHVFRzFVbjYtVGNUZHhMdTBIRTMwWFI0djh5UnByZFhBMGNVeEF2dUxfV0FkQ1Byc2hHc2lTazJ0dEVDd1ZEZjFJR1pudURncHJBbDJYM3gweGlMZi0yVmZJTl9xWk5seXp6aGRCb0R6MXJvUmVyX3B2QmpNci1TT0V3YUpjeldvcjBwZVI0TElqNzlZazJBZEFSYkNwQS1ieGs?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial - Slideshow (NASDAQ:NAMS) 2026-05-11", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNTE5heDlyY1pRT3g5U0xSUWVvNElrbDlYNUNrcG55MUdwS2JNX2Q4T2dqOF9rNEZkLTYtbDBSeC1Sb1JzWk5NZ1c1R19scC1FT01YOGtlOEtkLXU3TDE0Y0VNc1BYRkRVM1VxTFJLOUhtUUV6U0FBZkVDRGVmLTA1VlBCQkZpSmZKd2NHRVJyNVI2cE5FNnNaMjZVekpvUVNPY2k0QUdGek1XTFQtczEyMXNiQWhQSG9ZVDh0TEozaWJfTHNndUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPbklFUFBKR2ZOMnBCeGJFcXJ6d2JPSnlhQzNHSTd6TnN5dGI0a1ZrY1FCcDNVelQyTTVJaVhmT3dfQnpQMTIzNFpXMWRFT2pnVXl3YjlJQWFCeDl0N1l4TFBxd3ZEOTJVUzZGekUtd19GdUFISm5QSTNnd0ZwcHhTLTdibjdYUW1TTGdsM0ExZXFYYzNaeFVSV2tmX0I?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Do NewAmsterdam Pharma\u2019s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOT29qb21vYmtVYmRPNWRTZlVGYTIzbDhlejdldWJ0MzA3aU9JWHJQbmxkUEg1MDJhWTlCNjRPbUVYb1otNmdSdkhZQlo0c3pObkFxZTM1RGx1RUlPWmFlV2I5N1d3Z0FValNvVUFpODVIdGNwYWFMMzBTS09IUmNPNmdaZWFDY2xVR3pIenBrZ3R0QS1NVGRlaFJtMkpOaVJPSDQzOVNIRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOWkkzVHNRS3dyb1A1SHBKZUE5czU4TW1acXpiSXMwZFhSdkl6bE1hTmROSHV1Qno0MnBBdzRLamQ2R2tqQ0FlT3N6RHhsNVMwOHA3dmswclJNYUtpMEZaM24zVmtZU2RhZUdUS0xkQnJXeEpzbFFORURpSlFZTXFCWmpIMElSOUM3aV9KTnRKZ3AyWVV4NkV5ZmpQZUJYVWdlUGNkNHNsVzBnZFFScnhLODJnYm1Sdw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOM0RNZjRBLURuTWd5cTZ0VWRXWW1nbFQ0R0x5ZW1MQ2h5dzRJa0x0UC0zUDBXQkYzWEkzWGlBeHN3cENkLW1tQ3c5T2tMUEtRR2lzMW9LZ0MyRTRzTG1JWDBLRnRFMjBoTlFFdkNiZjVlaUdYa3BPbkN4SUVCWWNvYVZmMVJWbV9ic005aHB6dUtCLTFNVG1BNW0yN2xoSE9CR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib\u2019s Phase 3 LDL C Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxObDduR0pEaF80XzNKbV9YRU9tOW1tWmZPNkV5ODcxS3hYTjJBU0wzU2pTbThRQW9zMGxoV1RCMWdFY1R6X3EwSzdKeXp6dXNyRld1dV9BZWRWLTl0WnN2YWl6OXJoMjBHYVZBS2FzUU4zN1NfLVduRmpTSDNRR1UxQ2k0MWs4dHJuRGtOS2xndE9WQmF6U0llM0RMc3ZwVUNsMUV6UzBxVQ?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQSkFJTExwcFBBemFBVzRsNzNOYzdhMWRTVkZ2WlFrSFNZN1lwRi1vNV9Pa3l5MEJidU5NZHZsSlJPR293b1R6djU3dlRFajdmOGhjMFpaOXBRSVFabF9qRDNaQl9MaEtHQUxoTnB4ZURwc0NGSnpMX1pzNmVycnRBalNLRGpJeHVfZkVUaXpkdmhPalFQd1dndzVvYm1pZC12eTFadQ?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNZmg3REJTeTRPZ2QyNnNwVnZpakJuRTU5dGU5Vi05MHBGYk5FMTlLdmhKTlF2aE8xZXFEUzJDNEdBVm1SNG9QaFg5OGJHNzk4aURFRXZ5cWRJc2xNbm93QzhXTHlQNUxMMkdFTk9fU3lqd0JwR0Y5Z1VMU0hYZFFaRFl6aXI5bG8?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company Grants Inducement Share Options to New Hires", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQNy1HVTNnX2xWOHp3TkQtNlRaV1JadTB0LVBBR2xndmtqZEZDdkcxbkRXNl9rZTRRWmFkRjdTS0htUmQ1aDhQaTl0enVwNTJwU3hrb3NqamhOeDAtYUhianozU2x1WGR1ZXZFTkE3Z2ZBWmg2ZEVDSzBUX1RYeTFWcGNUSjcweHFZR3o0NjFEOEhtNTVTb1BDaFRNUlNjQngwYU14UzhIRW4?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "NewAmsterdam Pharma publishes obicetrapib Alzheimer\u2019s prevention research presentation", "summary": "NewAmsterdam Pharma has released a research presentation on the use of its CETP inhibitor, obicetrapib, for Alzheimer's prevention. A Phase 3 substudy showed that obicetrapib reduced plasma p-tau217 after 12 months, particularly in APOE4/E4 carriers, and positively impacted other", "url": "https://www.bitget.com/amp/news/detail/12560605512494", "source_name": "Bitget", "published_at": "2026-07-17T09:10:48", "published_display": "17 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. \u2013 MUN:KH6", "summary": "This article provides an analysis of the enterprise value to revenue forward for NewAmsterdam Pharma Company N.V. (MUN:KH6). It highlights financial data and market specifics for the company, listed on the Munich Stock Exchange. The information is presented within a financial dat", "url": "https://www.tradingview.com/symbols/MUN-KH6/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T05:11:58", "published_display": "14 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (NAMSW) for Rule-Based Strategy", "summary": "This article provides a price-driven insight for Newamsterdam Pharma Company N.v. Warrant (NASDAQ: NAMSW), detailing AI-generated trading strategies for different risk profiles. It highlights institutional trading strategies, multi-timeframe signal analysis, and real-time trading", "url": "https://news.stocktradersdaily.com/news_release/98/Price-Driven_Insight_from_NAMSW_for_Rule-Based_Strategy_071426032802_1784014082.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-14T03:11:58", "published_display": "14 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NewAmsterdam Pharma Company N.V. \u2013 NASDAQ:NAMS", "summary": "This article provides financial information for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), specifically focusing on its forward price-to-sales ratio. It presents various financial data points and market information for the company, accessible through TradingView. The conten", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T08:39:47", "published_display": "12 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company (NAMS) Study Update Summary", "summary": "NewAmsterdam Pharma Company (NAMS) provided an update on its BROOKLYN Phase III trial for obicetrapib, an investigational drug for Heterozygous familial hypercholesterolemia (HeFH). The study demonstrated that obicetrapib significantly reduced LDL-C by 36.3% at 84 days and 41.5% ", "url": "https://quartr.com/events/newamsterdam-pharma-company-n-v-nams-study-update_FL4O0nmu", "source_name": "Quartr", "published_at": "2026-07-10T21:10:48", "published_display": "10 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cambrex-snapdragon-chemistry-q1-scientific-120000213.html", "source_name": "CNW Group", "published_at": "2026-07-07T12:00:00+00:00", "published_display": "07 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma (NAMS) Alzheimer\u2019s Data Push Puts Fair Value Back In Focus", "summary": "NewAmsterdam Pharma (NAMS) is gaining attention due to its upcoming presentation of new obicetrapib data at the Alzheimer\u2019s Association International Conference, highlighting its potential in early Alzheimer's disease prevention. Despite trading at a premium on a price-to-book ba", "url": "https://www.sahmcapital.com/news/content/newamsterdam-pharma-nams-alzheimers-data-push-puts-fair-value-back-in-focus-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-06T06:39:14", "published_display": "06 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAMS - NewAmsterdam Pharma Company NV Latest SEC Filings", "summary": "This article provides the latest SEC filings information for NewAmsterdam Pharma Company NV (NAMS), including its last closing price, various financial metrics, stock performance data, and institutional/insider ownership details. It presents a comprehensive overview of the compan", "url": "https://finviz.com/stock?t=NAMS&ty=lf&p=d&b=1&page=3", "source_name": "Finviz", "published_at": "2026-07-03T17:09:09", "published_display": "03 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "NewAmsterdam Pharma N.V. announced inducement grants of share options and restricted stock units to four new non-executive hires under Nasdaq Listing Rule 5635(c)(4). The grants, made on July 1, 2026, include 28,700 ordinary shares for options with an exercise price of $35.17 and", "url": "https://finance.yahoo.com/healthcare/articles/newamsterdam-pharma-reports-inducement-grants-200100789.html", "source_name": "Market source", "published_at": "2026-07-03T04:40:12", "published_display": "03 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAMS - NewAmsterdam Pharma Company NV Options", "summary": "This article provides detailed financial data and performance metrics for NewAmsterdam Pharma Company NV (NAMS). It includes information on its last closing price, stock performance over various periods, key financial ratios, insider and institutional ownership, and analyst recom", "url": "https://finviz.com/stock?t=NAMS&ta=1&p=d&ty=oc&b=1", "source_name": "Finviz", "published_at": "2026-07-02T21:39:24", "published_display": "02 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma awards stock incentives to four new hires", "summary": "NewAmsterdam Pharma has granted equity awards to four new non-executive hires under its 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards consist of share options for 28,700 ordinary shares with an exercise price of $35.17 and 8,100 restricted st", "url": "https://www.stocktitan.net/news/NAMS/new-amsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-yxmzh17nef3k.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:33", "published_display": "02 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026", "summary": "NewAmsterdam Pharma N.V. announced it will present data on its drug obicetrapib as a potential therapy for early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. The presentations will highlight insights from the BROADWAY trial regarding pr", "url": "https://ca.finance.yahoo.com/news/newamsterdam-pharma-announces-upcoming-presentations-120000585.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-02T05:09:42", "published_display": "02 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is NewAmsterdam Pharma (NAMS) Quietly Reframing Its Alzheimer\u2019s Strategy With Obicetrapib\u2019s Multi\u2011Pathway Data?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T22:56:12+00:00", "published_display": "01 Jul 2026 22:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Announces Upcoming Presentations at the", "summary": "NewAmsterdam Pharma N.V. will present data on its investigational drug obicetrapib for the prevention of early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. The presentations will highlight insights from the BROADWAY trial regarding P-ta", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320530/0/en/newamsterdam-pharma-announces-upcoming-presentations-at-the-alzheimer-s-association-international-conference-aaic-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T11:39:58", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma puts obicetrapib in Alzheimer\u2019s spotlight at AAIC 2026", "summary": "NewAmsterdam Pharma will present multiple obicetrapib data sets related to Alzheimer's prevention at the Alzheimer's Association International Conference (AAIC) 2026 in London. The presentations will cover predictors of P-tau217, undiagnosed Alzheimer\u2019s pathology in cardiovascula", "url": "https://www.stocktitan.net/news/NAMS/new-amsterdam-pharma-announces-upcoming-presentations-at-the-ehajohcf4vdg.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:39:58", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V.", "summary": "This page provides access to NewAmsterdam Pharma Company N.V.'s SEC filings and other corporate documents, including earnings reports and event transcripts from various healthcare conferences. It details the company's financial performance, clinical trial advancements for Obicetr", "url": "https://www.tradingview.com/symbols/BOATS-NAMSW/documents/", "source_name": "TradingView", "published_at": "2026-07-01T10:39:58", "published_display": "01 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/newamsterdam-pharma-apos-obicetrapib-could-155741653.html", "source_name": "MT Newswires", "published_at": "2026-06-30T15:57:41+00:00", "published_display": "30 Jun 2026 15:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Raises Price Target on NewAmsterdam Pharma to $51 From $47, Keeps Outperform, Speculative Risk", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-raises-price-target-newamsterdam-112909411.html", "source_name": "MT Newswires", "published_at": "2026-06-30T11:29:09+00:00", "published_display": "30 Jun 2026 11:29", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NewAmsterdam Pharma Company N.V. \u2013 BOATS:NAMSW", "summary": "This article provides financial information for NewAmsterdam Pharma Company N.V. (NAMSW), specifically highlighting its price to sales forward metric. It also notes that the market for NAMSW is currently closed with no trades. The content is hosted on TradingView, which offers va", "url": "https://www.tradingview.com/symbols/BOATS-NAMSW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:39:50", "published_display": "29 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of NewAmsterdam Pharma Company N.V. \u2013 NASDAQ:NAMS", "summary": "This article provides the \"Price to book forward\" for NewAmsterdam Pharma Company N.V., traded under the NASDAQ symbol NAMS. It appears to be a financial data point from a market overview section, typical for platforms like TradingView. The content is concise, focusing solely on ", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:10:14", "published_display": "28 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. \u2013 NASDAQ:NAMSW", "summary": "This article provides the enterprise value to revenue forward for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW). The data presented shows the value, change, and percentage change for this financial metric. The information is sourced from TradingView, with market data from ICE ", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMSW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:11:04", "published_display": "28 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. \u2013 BOATS:NAMSW", "summary": "The article focuses on the enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. (NAMSW) as listed on the Blue Ocean Alternative Trade System. It provides a financial overview and market information for the company, indicating that the market is currently closed", "url": "https://www.tradingview.com/symbols/BOATS-NAMSW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T07:11:56", "published_display": "28 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of NewAmsterdam Pharma Company N.V. \u2013 LSX:A3DUAC", "summary": "This article provides the \"Price to book forward\" for NewAmsterdam Pharma Company N.V. (LSX:A3DUAC) on the Lang & Schwarz Exchange. The content highlights financial data and indicates that the market was closed with no trades. It also includes general disclaimers about data provi", "url": "https://www.tradingview.com/symbols/LSX-A3DUAC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:09:42", "published_display": "28 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of NewAmsterdam Pharma Company N.V. \u2013 NASDAQ:NAMSW", "summary": "This article provides the enterprise value to EBITDA forward for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW). It presents this financial metric for the company, indicating its market valuation relative to its earnings before interest, taxes, depreciation, and amortization. T", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMSW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:10:04", "published_display": "28 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. Actuals & Estimates (MUN:KH6)", "summary": "NewAmsterdam Pharma Company N.V. (KH6) financial actuals and estimates are detailed, including income statement, balance sheet, and cash flow data, as well as analyst forecasts. The article provides key financial metrics such as earnings per share, revenue, and EBITDA, and states", "url": "https://www.tradingview.com/symbols/MUN-KH6/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T14:41:27", "published_display": "27 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NAMS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "NewAmsterdam Pharma Company N.V. (NAMS) stock is currently trading at $33.24, with analysts predicting a future price range between $38.00 and $60.00. The company's stock has seen an 82.04% increase over the last year, and it is expected to release its next earnings report on Aug", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T14:11:04", "published_display": "27 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. Actuals & Estimates (NASDAQ:NAMS)", "summary": "This article provides an overview of NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) including its current stock price, historical performance, financial estimates, and analyst forecasts. It details financial actuals for revenue and earnings, future earnings dates, and general co", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T07:39:32", "published_display": "27 Jun 2026 07:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. Actuals & Estimates (HAM:KH6)", "summary": "This article provides an overview of NewAmsterdam Pharma Company N.V. (HAM:KH6) including its financial actuals and estimates, as well as analyst forecasts. It covers key financial data such as earnings, revenue, net income, and EBITDA, along with historical stock prices and futu", "url": "https://www.tradingview.com/symbols/HAM-KH6/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:32", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. \u2013 LSX:A3DUAC", "summary": "This article provides financial data for NewAmsterdam Pharma Company N.V. (LSX: A3DUAC), specifically focusing on its enterprise value to revenue forward. The content is primarily a data placeholder from TradingView, offering a snapshot of the company's financial overview without", "url": "https://www.tradingview.com/symbols/LSX-A3DUAC/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:10:00", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. Actuals & Estimates (LSX:A3DUAC)", "summary": "This article provides actuals and estimates for NewAmsterdam Pharma Company N.V. (LSX:A3DUAC), detailing financial data, analyst forecasts, and various stock performance metrics. It covers information on the company's stock price, market capitalization, earnings, revenue, and fut", "url": "https://www.tradingview.com/symbols/LSX-A3DUAC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:00", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of NewAmsterdam Pharma Company N.V. \u2013 NASDAQ:NAMS", "summary": "This article provides the \"Price to earnings forward\" value for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS). It specifies that the market is currently closed and no trades have occurred. The content appears to be a stub or a section of a larger financial data display from Tra", "url": "https://www.tradingview.com/symbols/NASDAQ-NAMS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T03:40:39", "published_display": "25 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma (NAMS) CAO exercises options and sells 40,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOZk10UWRIaGp2QW1hclh5MTUtTWZrcUE3Wld4U0ZUMnFxRlNmS3c3QmZfQUtjRWhRZjMwa05mYm5HWHJ1M2t5ajZkTG81M0JoczA2ZDRjdjVNbGtMeHpCcjRSb1ZVQ285TU51enozT01nV1VEVzdVdTlmaU41cEZzWWtEYV9waHpoWGFucE5wUWF4VXhZX1BUQVhlRGhRQ3VyV25mX3h1cF9WcFYzZXdXcXI2UF94c1VzckhjcjBB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNdjlSR3Z1RnQtNUNnSWxfX2RtMGpudUo5NFFXSzVGNXIzVEdVYUs5dkZxME1uQlUtY3Rhb29fd2ZSVEd2R1JnMklPSGd5UkxqR19FUHpyby11RkZ3VUNuQ25xX2hNc1BUZFFVWFRCa25ZQ1AxNTRKT24wLWtTOHQzZDJLamRsTUpReWVtb3l6czdnalZacmR1TFFKUUpPV2NRenY5NHdoZw?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/billionaire-stanley-druckenmiller-likes-small-142953263.html", "source_name": "Insider Monkey", "published_at": "2026-06-08T14:29:53+00:00", "published_display": "08 Jun 2026 14:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/newamsterdam-pharma-announces-upcoming-presentations-120000543.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:00:00+00:00", "published_display": "03 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech NewAmsterdam to appear at two June healthcare investor events", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNVG94TXV4UV9MSVF0UGZ1UjVRUjAxak1TclZaMU5maHVFRzFVbjYtVGNUZHhMdTBIRTMwWFI0djh5UnByZFhBMGNVeEF2dUxfV0FkQ1Byc2hHc2lTazJ0dEVDd1ZEZjFJR1pudURncHJBbDJYM3gweGlMZi0yVmZJTl9xWk5seXp6aGRCb0R6MXJvUmVyX3B2QmpNci1TT0V3YUpjeldvcjBwZVI0TElqNzlZazJBZEFSYkNwQS1ieGs?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial - Slideshow (NASDAQ:NAMS) 2026-05-11", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNTE5heDlyY1pRT3g5U0xSUWVvNElrbDlYNUNrcG55MUdwS2JNX2Q4T2dqOF9rNEZkLTYtbDBSeC1Sb1JzWk5NZ1c1R19scC1FT01YOGtlOEtkLXU3TDE0Y0VNc1BYRkRVM1VxTFJLOUhtUUV6U0FBZkVDRGVmLTA1VlBCQkZpSmZKd2NHRVJyNVI2cE5FNnNaMjZVekpvUVNPY2k0QUdGek1XTFQtczEyMXNiQWhQSG9ZVDh0TEozaWJfTHNndUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPbklFUFBKR2ZOMnBCeGJFcXJ6d2JPSnlhQzNHSTd6TnN5dGI0a1ZrY1FCcDNVelQyTTVJaVhmT3dfQnpQMTIzNFpXMWRFT2pnVXl3YjlJQWFCeDl0N1l4TFBxd3ZEOTJVUzZGekUtd19GdUFISm5QSTNnd0ZwcHhTLTdibjdYUW1TTGdsM0ExZXFYYzNaeFVSV2tmX0I?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Do NewAmsterdam Pharma\u2019s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOT29qb21vYmtVYmRPNWRTZlVGYTIzbDhlejdldWJ0MzA3aU9JWHJQbmxkUEg1MDJhWTlCNjRPbUVYb1otNmdSdkhZQlo0c3pObkFxZTM1RGx1RUlPWmFlV2I5N1d3Z0FValNvVUFpODVIdGNwYWFMMzBTS09IUmNPNmdaZWFDY2xVR3pIenBrZ3R0QS1NVGRlaFJtMkpOaVJPSDQzOVNIRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOWkkzVHNRS3dyb1A1SHBKZUE5czU4TW1acXpiSXMwZFhSdkl6bE1hTmROSHV1Qno0MnBBdzRLamQ2R2tqQ0FlT3N6RHhsNVMwOHA3dmswclJNYUtpMEZaM24zVmtZU2RhZUdUS0xkQnJXeEpzbFFORURpSlFZTXFCWmpIMElSOUM3aV9KTnRKZ3AyWVV4NkV5ZmpQZUJYVWdlUGNkNHNsVzBnZFFScnhLODJnYm1Sdw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOM0RNZjRBLURuTWd5cTZ0VWRXWW1nbFQ0R0x5ZW1MQ2h5dzRJa0x0UC0zUDBXQkYzWEkzWGlBeHN3cENkLW1tQ3c5T2tMUEtRR2lzMW9LZ0MyRTRzTG1JWDBLRnRFMjBoTlFFdkNiZjVlaUdYa3BPbkN4SUVCWWNvYVZmMVJWbV9ic005aHB6dUtCLTFNVG1BNW0yN2xoSE9CR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib\u2019s Phase 3 LDL C Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxObDduR0pEaF80XzNKbV9YRU9tOW1tWmZPNkV5ODcxS3hYTjJBU0wzU2pTbThRQW9zMGxoV1RCMWdFY1R6X3EwSzdKeXp6dXNyRld1dV9BZWRWLTl0WnN2YWl6OXJoMjBHYVZBS2FzUU4zN1NfLVduRmpTSDNRR1UxQ2k0MWs4dHJuRGtOS2xndE9WQmF6U0llM0RMc3ZwVUNsMUV6UzBxVQ?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQSkFJTExwcFBBemFBVzRsNzNOYzdhMWRTVkZ2WlFrSFNZN1lwRi1vNV9Pa3l5MEJidU5NZHZsSlJPR293b1R6djU3dlRFajdmOGhjMFpaOXBRSVFabF9qRDNaQl9MaEtHQUxoTnB4ZURwc0NGSnpMX1pzNmVycnRBalNLRGpJeHVfZkVUaXpkdmhPalFQd1dndzVvYm1pZC12eTFadQ?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNZmg3REJTeTRPZ2QyNnNwVnZpakJuRTU5dGU5Vi05MHBGYk5FMTlLdmhKTlF2aE8xZXFEUzJDNEdBVm1SNG9QaFg5OGJHNzk4aURFRXZ5cWRJc2xNbm93QzhXTHlQNUxMMkdFTk9fU3lqd0JwR0Y5Z1VMU0hYZFFaRFl6aXI5bG8?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewAmsterdam Pharma Company Grants Inducement Share Options to New Hires", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQNy1HVTNnX2xWOHp3TkQtNlRaV1JadTB0LVBBR2xndmtqZEZDdkcxbkRXNl9rZTRRWmFkRjdTS0htUmQ1aDhQaTl0enVwNTJwU3hrb3NqamhOeDAtYUhianozU2x1WGR1ZXZFTkE3Z2ZBWmg2ZEVDSzBUX1RYeTFWcGNUSjcweHFZR3o0NjFEOEhtNTVTb1BDaFRNUlNjQngwYU14UzhIRW4?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 54, "sentiment_summary": {"positive": 13, "negative": 3, "neutral": 38, "score": 55, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 13.55, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 13.2, "count": 26}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 13, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 31.68, "latest_week": "2026-07-17", "one_week_move": -10.2, "four_week_move": 6.2, "twelve_week_move": 6.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.06132, "market_dynamics_buy_signal": false, "relative_strength": -11.756589, "fair_value_gap": 40.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.359, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.2% over one week, +6.2% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 16}, {"label": "Market source", "count": 15}, {"label": "Stock Titan", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Finviz", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "Bitget", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 26}, {"label": "Market update", "count": 24}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.2% over one week, +6.2% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "NewAmsterdam Pharma publishes obicetrapib Alzheimer\u2019s prevention research presentation"}], "updated_at": "2026-07-19T18:10:46.384681+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}